STOCK TITAN

Instil Bio (TIL) Stock Price, News & Analysis

TIL NASDAQ
Published by Stock Titan Data refreshed

Why is TIL Stock Down Today?

9.39% today
14 alerts
3.0x vol
15m delay

Instil Bio, Inc. (TIL)’s third-quarter results and corporate update may be relevant to investor sentiment; the company released them on November 16, before today’s session. The company’s 8-K reported a third-quarter net loss of $4.231 million and said its $67.091 million in cash and investments was expected to fund its operating plan through 2027.

AI-generated explanation by Rhea-AI, written on at . How Rhea-AI works. Not financial advice.

Price Move History

Daily moves over 5%
25 252 sessions, November 14, 2025 to November 16, 2026
Largest daily move
-45.8% close of January 6, 2026
1-year change
-60.1% closing prices, November 14, 2025 to November 16, 2026
1-month change
-2.7% closing prices, October 16, 2026 to November 16, 2026

Company Description

Instil Bio, Inc. (TIL) is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies for cancer and other serious diseases. The company is described in its public communications as a clinical-stage biopharmaceutical organization, emphasizing research and development activities rather than commercialized products.

Across multiple press releases, Instil Bio highlights a focus on novel therapies, with particular attention to a lead asset known as AXN-2510 (also referred to as IMM2510/AXN-2510 or "’2510"). AXN-2510 is characterized as a PD-L1xVEGF bispecific antibody in development for the treatment of multiple solid tumors, including advanced non-small cell lung cancer (NSCLC). This bispecific antibody targets PD-L1 and VEGF pathways, and is described as differentiated from other PD-(L)1xVEGF bispecific antibodies by its VEGF trap design, its use of PD-L1 as an anchor in the tumor microenvironment, and enhanced antibody-dependent cellular cytotoxicity (ADCC) for direct killing of PD-L1-positive tumor cells, according to company and collaborator disclosures.

Instil Bio operates in the research and development in biotechnology space within the broader professional, scientific, and technical services sector. The company identifies itself as clinical-stage, meaning its programs are in clinical testing rather than commercial deployment. Public filings and press releases indicate that Instil Bio is listed on Nasdaq under the ticker symbol TIL.

Lead program and clinical focus

Instil Bio’s lead program, AXN-2510, is repeatedly described in company and collaborator announcements as a PD-L1xVEGF bispecific antibody in development for multiple solid tumors. Company communications note that AXN-2510 is being evaluated in different clinical settings, including:

  • Monotherapy for patients with relapsed or refractory solid tumors, with a Phase 1 trial design described as assessing safety, efficacy, pharmacokinetics, and pharmacodynamics.
  • Combination with chemotherapy for front-line advanced non-small cell lung cancer (NSCLC) in a Phase 2 open-label, multicenter study conducted in China by ImmuneOnco Biopharmaceuticals (Shanghai) Inc. (ImmuneOnco), as reported in joint announcements.
  • Monotherapy in patients with previously treated squamous non-small cell lung cancer (sq-NSCLC) in a Phase 1 study in China conducted by ImmuneOnco, with preliminary safety and efficacy data described in Instil Bio and ImmuneOnco communications.

According to these disclosures, preliminary data from ImmuneOnco’s studies of ’2510 in NSCLC settings have included objective response rates and safety observations, which Instil Bio has highlighted in its own news releases and in an 8-K filing referencing ImmuneOnco’s Phase 2 chemo combination trial data.

Collaboration with ImmuneOnco and Axion Bio subsidiary

Instil Bio’s public materials describe a collaboration with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. around AXN-2510/IMM2510. ImmuneOnco conducts clinical trials of ’2510 in China, including monotherapy and combination chemotherapy trials in NSCLC, and shares preliminary safety and efficacy data that Instil Bio reports in its own news and regulatory filings.

Instil Bio also discloses that Axion Bio, Inc. is a wholly-owned subsidiary dedicated to the development of AXN-2510. Announcements describe Axion Bio’s role in advancing ’2510, including dosing the first patient in a Phase 1 clinical trial of ’2510 monotherapy in adult patients with advanced solid tumors. Later, Instil Bio reports that Axion decided to discontinue clinical development of AXN-2510 and that Axion and ImmuneOnco entered into a Termination Agreement under which all rights previously licensed to Axion, including global development and commercial rights outside Greater China, reverted to ImmuneOnco, subject to a limited license to Axion to wind down its clinical development activities.

Pipeline evolution and historical context

In earlier third-party descriptions, Instil Bio was described as focused on developing a cell therapy pipeline of autologous tumor infiltrating lymphocyte (TIL) therapies for cancer and on a Co-Stimulatory Antigen Receptor (CoStAR) platform, with a pipeline including ITIL-306. Instil Bio, Inc. also targets tumor-associated antigens expressed on solid tumors such as ovarian cancer, uterine cancer, NSCLC, and renal cancer. More recent company press releases, however, consistently emphasize AXN-2510 as the lead asset and describe Instil Bio as a clinical-stage biopharmaceutical company focused on a pipeline of novel therapies, with repeated reference to PD-L1xVEGF bispecific antibody development for multiple solid tumors.

Investors reviewing Instil Bio should note that the company’s more recent disclosures focus on AXN-2510 and related collaborations, while the earlier cell therapy and CoStAR platform description may reflect a prior stage in the company’s development. The shift in emphasis in public communications provides context for understanding the evolution of Instil Bio’s research and development priorities.

Regulatory filings and financial reporting

Instil Bio files periodic and current reports with the U.S. Securities and Exchange Commission (SEC). Recent Form 8-K filings reference:

  • Quarterly financial results and corporate updates, including operating expenses such as research and development, general and administrative expenses, and restructuring and impairment charges.
  • Use of non-GAAP financial measures, such as non-GAAP net loss and non-GAAP net loss per share, defined as excluding non-cash stock-based compensation expense and restructuring and impairment charges. The company explains in press releases and reconciliations that it believes these non-GAAP measures, when considered with GAAP figures, can enhance understanding of its financial performance and are among the indicators used for planning and performance measurement.
  • Disclosure of preliminary safety and efficacy data from ImmuneOnco’s Phase 2 chemo combination trial of ’2510 in front-line NSCLC, including partial response rates and safety observations, as an Other Events item.

These filings provide insight into Instil Bio’s operating expenses, net losses, and the role of restructuring and non-cash charges in its reported results, as well as the company’s approach to presenting non-GAAP metrics.

Corporate developments and leadership

Instil Bio’s news releases describe several corporate developments relevant to its clinical programs and governance, including:

  • The appointment of a Chief Medical Officer with experience in oncology drug development and a background in leading programs through various phases of development, regulatory approval, and commercialization.
  • The addition of an experienced biotechnology executive to the Board of Directors of Axion Bio, Inc., described as bringing decades of experience in building and leading life sciences companies and advancing therapeutic modalities.
  • Participation in healthcare investment conferences and joint investor and research analyst events with ImmuneOnco to discuss the PD-(L)1xVEGF bispecific antibody landscape and clinical trial updates.

These disclosures underscore the company’s emphasis on clinical development expertise and external engagement around its PD-L1xVEGF bispecific antibody program.

Business model and sector positioning

According to its public statements, Instil Bio’s business model centers on clinical research and development of novel therapies, particularly antibody-based approaches such as PD-L1xVEGF bispecific antibodies. As a clinical-stage biopharmaceutical company, it focuses on advancing investigational therapies through early- and mid-stage clinical trials, often in collaboration with partners such as ImmuneOnco.

The company operates within the biotechnology research and development industry, part of the professional, scientific, and technical services sector. Its activities include designing and conducting clinical trials, analyzing safety and efficacy data, and managing collaborations and licensing arrangements related to its investigational therapies.

Key points for investors and observers

  • Instil Bio is a clinical-stage biopharmaceutical company focused on developing a pipeline of novel therapies.
  • The company’s lead asset, AXN-2510 (IMM2510/AXN-2510), is a PD-L1xVEGF bispecific antibody in development for multiple solid tumors, including NSCLC settings studied by ImmuneOnco.
  • Instil Bio collaborates with ImmuneOnco Biopharmaceuticals (Shanghai) Inc. on clinical development of ’2510 in China and has used its wholly-owned subsidiary, Axion Bio, Inc., to advance AXN-2510, with later disclosure of Axion’s decision to discontinue its clinical development of AXN-2510 and the reversion of licensed rights to ImmuneOnco.
  • Regulatory filings and press releases provide detailed information on financial results, non-GAAP measures, and clinical trial updates related to AXN-2510.

Stock Performance

$5.21
-9.39%
-0.54
Last updated: November 17, 2026 at 13:33
-60.1%
Performance 1 year
$35.3M

Instil Bio (TIL) closed at $5.75 on November 16, 2026. Over the past 12 months, the price has lost 60.1%.

See what a $1,000 investment in TIL would be worth today

Average down calculator for TIL

TIL Metrics & Rankings

Price returns through November 16, 2026. Month and year figures include the first trading day. Ranking links may use different dates.

Latest News

Instil Bio has 10 recent news articles, with the latest published yesterday. Of the recent coverage, 4 articles coincided with positive price movement and 5 with negative movement. Key topics include earnings, clinical trial. View all TIL news →

Financial Highlights

Instil Bio reported operating income of -$78.6M in FY2025, and net income was -$71.4M. Diluted earnings per share stood at -$10.70. The company generated -$36.6M in operating cash flow. The current ratio was 27.37, measuring current assets divided by current liabilities.

-$71.4M
Net Income (FY2025)
-$36.6M
Operating Cash Flow
—
Revenue (FY2025)

Upcoming Events

YEAR
2027
2027 Financial

Cash runway through 2027

Company reports $67.1M cash at Sept 30, 2026 and expects these resources to fund its operating plan through 2027.

Instil Bio has 1 upcoming scheduled event. The next event, "Cash runway through 2027", is expected in 2027. It is a financing or capital event, such as a dividend or a debt maturity. Investors can track these dates to stay informed about potential catalysts that may affect the TIL stock price.

Short Interest History

Last 12 Months

Short interest in Instil Bio (TIL) currently stands at 181.2 thousand shares, up 6.3% from the previous reporting period, representing 3.0% of the float. Since November 2025, short interest has decreased by 67.0%.

Days to Cover History

Last 12 Months

Days to cover for Instil Bio (TIL) currently stands at 2.3 days, down 66.2% from the previous period. The ratio is the reported short interest divided by the average daily trading volume. Since November 2025, the figure has decreased by 63.8%. Across the settlements charted above, it has ranged from 1.1 to 22.9 days.

TIL Company Profile & Sector Positioning

Instil Bio (TIL) operates in the Biotechnology industry within the broader Healthcare sector and is listed on the NASDAQ.

Investors comparing TIL often look at related companies in the same sector, including Pliant Therapeutics, Inc. (PLRX), Annovis Bio, Inc. (ANVS), ImageneBio, Inc. (IMA), Connect Biopharma Holdings Limited (CNTB), and Dogwood Therapeutics, Inc. (DWTX). Comparing financial metrics, valuation ratios, and stock performance across these peers can help investors evaluate TIL's relative position within its industry.

Frequently Asked Questions

The current stock price of Instil Bio (TIL) is $5.21 as of November 17, 2026.

The market cap of Instil Bio (TIL) is approximately $35.3M. Learn more about what market capitalization means .

The FY2025 net income of Instil Bio (TIL) is -$71.4M, from its most recent completed fiscal year.

The diluted earnings per share (EPS) of Instil Bio (TIL) is -$10.70 for FY2025, its most recent completed fiscal year. Learn more about EPS .

The operating cash flow of Instil Bio (TIL) is -$36.6M for FY2025, its most recent completed fiscal year. Learn about cash flow.

The current ratio of Instil Bio (TIL), current assets divided by current liabilities, was 27.37 at the end of FY2025, its most recent completed fiscal year. Learn about liquidity ratios.

The operating income of Instil Bio (TIL) is -$78.6M for FY2025, its most recent completed fiscal year. Learn about operating income.